app.info.haymarketmedicalnetwork.com Open in urlscan Pro
147.154.2.128  Public Scan

URL: https://app.info.haymarketmedicalnetwork.com/e/es?s=2255121&e=146697&elqTrackId=efd74c1a1b7a40299e524d6e5aa03bea&elq=f18e871fdc404a49859e8a8a...
Submission: On April 24 via manual from US — Scanned from DE

Form analysis 0 forms found in the DOM

Text Content

If you are having trouble viewing this email, read the online version.
‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌
‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌
‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌
‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌
‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌

PCP Management of Anemia in CKD: From Screening to Referral Implement
Evidence-Based Care in Patients
Chronic kidney disease (CKD) is an important public health issue in the United
States as it affects approximately 15% of the adult population. Yet, the vast
majority of patients are unaware of their disease. The collective toll taken by
CKD and its most advanced stage, end-stage renal disease (ESRD), on patient
health and the healthcare system is enormous in scope. CKD is associated with
poor physical and mental health; decreased functional status, work productivity,
and health-related quality of life (HRQoL); significant morbidity; and premature
mortality. However, CKD is largely a silent disease. The vast majority of
patients with CKD and nearly half with severe CKD are unaware of their disease
and are undiagnosed. Anemia is a common complication of CKD, with estimates
indicating that anemia is twice as prevalent in people with CKD compared with
the general population. The prevalence and severity of anemia increase as CKD
progresses, which means the majority of patients with CKD stage 5 develop
anemia. Thus, the stage of CKD is the main risk factor for anemia. The
pathophysiology of anemia in CKD is multifactorial and complex, but the dominant
contributing factors are inadequate production of erythropoietin (EPO) and iron
deficiency. This course will address diagnosis and treatment to optimize patient
care.


This webcast was recorded live at the Emerging Challenges and Clinical Update
Live Virtual Broadcast and is being used with the permission of the presenters.
Earn 1.00 / AMA PRA Category 1 Credit™ or 1.00 / AANP Contact Hour.
Begin Activity ►

--------------------------------------------------------------------------------

FACULTY
Robert D. Toto, MD
Professor of Medicine
Medical Director, Kidney Liver Outpatient Clinic
UT Southwestern Medical Center
Dallas, TX
MODERATOR
Gregg Sherman, MD
Chief Medical Officer
Course Director
National Association for Continuing Education
Plantation, FL

--------------------------------------------------------------------------------

CLICK HERE TO START NOW




Haymarket Media, Inc.

461 From Road, Suite 198, Paramus, NJ 07652

Privacy Policy | Terms & Conditions

You have received this email communication based upon your profession and
specialty.

If you wish to unsubscribe from myCME, click here.

Manage your email preferences for the Haymarket Medical Network.

Unsubscribe from all emails from the Haymarket Medical Network.